PMA Sponsors Given Opportunity To Submit Proposed Panel Package
This article was originally published in The Gray Sheet
Sponsors of panel-track premarket approval applications wishing to submit a proposed panel package to FDA must do so at least four weeks prior to the scheduled meeting date, according to FDA's March 20 "Guidance on Amended Procedures for Advisory Panel Meetings."
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.